跳至主要内容
临床试验/NCT01324336
NCT01324336已完成不适用

Comparative Pharmacokinetics of a Compounded 6-mercaptopurine Liquid Formulation Preparation and Tablets

Children's Mercy Hospital Kansas City1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2011年7月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
40
试验地点
1
主要终点
Pharmacokinetics of 6-MP

研究概览

简要总结

The purpose of this study is to compare the pharmacokinetics of a routinely used compounded liquid formulation of 6-mercaptopurine (6-MP) with commercially available tablets in patients who are receiving treatment with 6-MP as part of their clinical treatment for acute lymphoblastic leukemia (ALL).

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
4 Years 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Patients ages 4-17 years of age who are receiving maintenance chemotherapy treatment for ALL with 6-MP will be included.

排除标准

  • Inability to have blood drawn for the screening lab tests
  • Received methotrexate or folate supplement within the last 24 hours
  • Pregnant or lactating females
  • Inability to swallow a pill
  • Hemoglobin less or equal to 8 gm/dl
  • Presence of significant co-morbid illness that makes child ineligible as deemed by the investigator
  • Weight < or = 16 kg

研究组 & 干预措施

4-17 years, receiving 6-MP

干预措施: 6-Mercaptopurine (Drug)

结局指标

主要结局

Pharmacokinetics of 6-MP

时间窗: 8 hours post administration

To compare the pharmacokinetics of a routinely used compounded liquid formulation of 6-mercaptopurine (6-MP) with commercially available tablets in patients who are receiving treatment with 6-MP as part of their clinical treatment for acute lymphoblastic leukemia (ALL).

次要结局

未报告次要终点

研究者

发起方
Children's Mercy Hospital Kansas City
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验